Changes in Sexual Behaviors in Men Who Have Sex with Men: A Comparison Between the Double-Blind and Open-Label Extension Phases of the ANRS-IPERGAY Trial.
Adult
Anti-HIV Agents
/ administration & dosage
Canada
Double-Blind Method
France
HIV Infections
/ prevention & control
Homosexuality, Male
Humans
Male
Middle Aged
Pre-Exposure Prophylaxis
/ methods
Risk Reduction Behavior
Risk-Taking
Safe Sex
Sexual Behavior
/ statistics & numerical data
Sexual Partners
Young Adult
ANRS-IPERGAY trial
Behaviors
HIV risk management
MSM
PrEP
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
20
4
2020
medline:
30
9
2020
entrez:
20
4
2020
Statut:
ppublish
Résumé
Pre-Exposure Prophylaxis (PrEP) is changing the landscape of HIV prevention, and may bring changes in sexual behaviors. The double-blind phase (DBP) and open-label extension (OLE) study of the ANRS-IPERGAY trial allowed us to assess changes in sexual behavior of men who have sex with men (MSM) taking sexual activity-based (i.e., on-demand) PrEP. Generalized Estimating Equation (GEE) models found a significant decrease in the number of sexual partners (Coefficient [CI95%], p value; - 0.37[- 0.70 to - 0.04], p = 0.03) between the DBP and OLE as well as in the number of sexual relations (- 0.25 [- 0.49 to 0.00], 0.04). GEE estimates also showed that respondents' most recent sexual relation was less likely to have been with an unknown casual partner during the OLE than during the DBP (Odds Ratio [CI95%], p value: 0.75[0.62-0.92], 0.005). Furthermore, they showed an increase in the proportion of condomless anal sex in the OLE (1.32[1.04-1.67], 0.02), a decrease in the proportion of 'suboptimal PrEP adherence' over time (0.75[0.58-0.97], p = 0.03), a decrease in PrEP only use (0.73[0.55-0.96], 0.03) and in both PrEP and condom use over time (0.70[0.51-0.95], 0.02) and finally, a decrease in alcohol consumption between the DBP and OLE (0.74[0.61-0.90], 0.002). We observed both protective and risky behaviors in terms of HIV and STI risk after on-demand PrEP uptake in the OLE phase. Our findings are consistent with results from previous PrEP trials.
Identifiants
pubmed: 32306213
doi: 10.1007/s10461-020-02864-8
pii: 10.1007/s10461-020-02864-8
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3093-3106Investigateurs
J-M Molina
(JM)
C Capitant
(C)
B Spire
(B)
G Pialoux
(G)
L Cotte
(L)
I Charreau
(I)
C Tremblay
(C)
J-M Le Gall
(JM)
E Cua
(E)
A Pasquet
(A)
F Raffi
(F)
C Pintado
(C)
C Chidiac
(C)
J Chas
(J)
P Charbonneau
(P)
C Delaugerre
(C)
M Suzan-Monti
(M)
B Loze
(B)
J Fonsart
(J)
G Peytavin
(G)
A Cheret
(A)
J Timsit
(J)
G Girard
(G)
N Lorente
(N)
M Préau
(M)
J F Rooney
(JF)
M A Wainberg
(MA)
D Thompson
(D)
W Rozenbaum
(W)
V Doré
(V)
L Marchand
(L)
M-C Simon
(MC)
N Etien
(N)
J-P Aboulker
(JP)
L Meyer
(L)
J-F Delfraissy
(JF)
C Pintado
(C)
B Loze
(B)
C Delaugerre
(C)
P Charbonneau
(P)
C Gatey
(C)
D Ponscarme
(D)
P Penot
(P)
L Niedbalski
(L)
R Veron
(R)
J Delgado
(J)
E Dalle
(E)
S Parlier
(S)
I Madelaine
(I)
J Fonsart
(J)
M Danet
(M)
N Mahjoub
(N)
N Mezreb
(N)
K Moudachirou
(K)
S Morel
(S)
G Conort
(G)
F Lorho
(F)
M Meunier
(M)
W Rozenbaum
(W)
J M Molina
(JM)
J Chas
(J)
C Monfort
(C)
J Foucoin
(J)
B Boissavy
(B)
S Cousseau
(S)
S Huon
(S)
M Danet
(M)
A Djessima
(A)
V Berrebi
(V)
A Adda
(A)
S le Nagat
(S)
L Zarka
(L)
J Berdougo
(J)
G Pialoux
(G)
C Chidiac
(C)
N Mzoughi
(N)
F Clement
(F)
A Decouty
(A)
C Chapolard
(C)
M Godinot
(M)
C Adouard-Groslafeige
(C)
J Koffi
(J)
A Pansu
(A)
A Becker
(A)
S Pailhes
(S)
F Bonnet
(F)
F Jeanblanc
(F)
C Brochier
(C)
X Teruin
(X)
S Rouby
(S)
L Gilly
(L)
L Cotte
(L)
C Beauvais
(C)
P Arlotto
(P)
C Fortin
(C)
A Talbot
(A)
A Chamberland
(A)
A McKenzie
(A)
M Blanchette
(M)
R Rousseau
(R)
K Montheuth
(K)
D Thompson
(D)
M Morin
(M)
M Wainberg
(M)
C Tremblay
(C)
C Etienne
(C)
F Tolonin
(F)
S Breaud
(S)
V Péchenot
(V)
S Bagge
(S)
T Cepitelli
(T)
P M Roger
(PM)
E Rosenthal
(E)
E Cua
(E)
A Cheret
(A)
P Cornavin
(P)
S Vandamme
(S)
J Lambec
(J)
N Dumon
(N)
O Leclanche
(O)
T Huleux
(T)
R Biekre
(R)
O Robineau
(O)
H Melliez
(H)
H Bazus
(H)
A Pasquet
(A)
C Bernaud
(C)
M Besnier
(M)
B Bonnet
(B)
N Hall
(N)
M Cavellec
(M)
H Hue
(H)
L Larmet
(L)
M Colas
(M)
R Choquet
(R)
F Raffi
(F)
Références
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
doi: 10.1056/NEJMoa1011205
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016;387(10013):53–60.
doi: 10.1016/S0140-6736(15)00056-2
Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.
doi: 10.1056/NEJMoa1506273
Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165–72.
doi: 10.1007/s11904-007-0024-7
Hogben M, Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis. 2008;35(12):1009–100.
pubmed: 18936724
Collin J, David P-M, editors. Vers une pharmaceuticalisation de la société? le médicament comme objet social. Québec: Presses de l’Université du Québec; 2016 (Problèmes sociaux et interventions sociales).
Rojas Castro D, Delabre RM, Molina J. Give PrEP a chance: moving on from the “risk compensation” concept. J Int AIDS Soc. 2019. https://doi.org/10.1002/jia2.25351 .
doi: 10.1002/jia2.25351
pubmed: 31468710
pmcid: 6715948
Golub SA, Gamarel KE, Surace A. Demographic differences in PrEP-related stereotypes: implications for implementation. AIDS Behav. 2017;21(5):1229–355.
doi: 10.1007/s10461-015-1129-4
Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–e410410.
doi: 10.1016/S2352-3018(17)30089-9
Girard G. “La pilule qui change tout ?” analyse des débats québécois autour de la prophylaxie préexposition du VIH. In: Vers une pharmaceuticalisation de la société. Québec: Presses de l’Université du Québec; 2016. p. 193–218.
Kalampalikis N, Apostolidis T. La perspective socio-génétique des représentations sociales. In: Les représentations sociales. De Boeck. Bruxelles: De Boeck; 2016. p. 69–85. (Ouvertures Psychologiques).
Jansen M, Tromp N, Baltussen R. PrEP: why we are waiting. Lancet HIV. 2016;3:e11–e12.
doi: 10.1016/S2352-3018(15)00250-7
Otis J, Lévy JJ-, Bernier M, editors. La recherche communautaire VIH/sida: des savoirs engagés. Québec (Québec): Presses de l’Université du Québec; 2015 (Collection Santé et société).
Glasgow RE, Eckstein ET, ElZarrad MK. Implementation science perspectives and opportunities for HIV/AIDS research: integrating science, practice, and policy. JAIDS J Acquir Immune Defic Syndr. 2013;63:S26–S31.
doi: 10.1097/QAI.0b013e3182920286
Morin M, Apostolidis T. Contexte social et santé. In: Traité de psychologie de la santé. Dunod. Paris: Gustave-Nicolas Fisher; 2002.
Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. Sexual risk behavior among HIV-Uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr. 2013;64(1):87–94.
doi: 10.1097/QAI.0b013e31828f097a
Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, et al. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. AIDS Care. 2016;28(sup 1):48–55.
doi: 10.1080/09540121.2016.1146653
Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral hiv preexposure prophylaxis. PLoS ONE. 2013;8(12):e81997.
doi: 10.1371/journal.pone.0081997
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.
doi: 10.1016/S1473-3099(14)70847-3
Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75.
doi: 10.1001/jamainternmed.2015.4683
Oldenburg CE, Nunn AS, Montgomery M, Almonte A, Mena L, Patel RR, et al. Behavioral changes following uptake of HIV pre-exposure prophylaxis among men who have sex with men in a clinical setting. AIDS Behav. 2018;22(4):1075–9.
doi: 10.1007/s10461-017-1701-1
Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of hiv preexposure prophylaxis in a clinical practice setting: figure 1. Clin Infect Dis. 2015;61(10):1601–3.
doi: 10.1093/cid/civ778
Amico KR, Mehrotra M, Avelino-Silva VI, McMahan V, Veloso VG, et al. Self-reported recent PrEP dosing and drug detection in an open label PrEP study. AIDS Behav. 2016;20(7):1535–40.
doi: 10.1007/s10461-016-1360-7
Zeger SL, Liang K-Y, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049.
doi: 10.2307/2531734
Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121.
doi: 10.2307/2531248
Spinelli MA, Buchbinder SP. Pre-exposure prophylaxis persistence is a critical issue in PrEP implementation. Clin Infect Dis. 2019. https://doi.org/10.1093/cid/ciz896 .
doi: 10.1093/cid/ciz896
pmcid: 7384308
Rolle C-P, Onwubiko U, Jo J, Sheth AN, Kelley CF, Holland DP. PrEP implementation and persistence in a county health department setting in Atlanta. GA AIDS Behav. 2019;23(S3):296–303.
doi: 10.1007/s10461-019-02654-x
D’Angelo AB, Lopez-Rios J, Flynn AWP, Holloway IW, Pantalone DW, Grov C. Insurance- and medical provider-related barriers and facilitators to staying on PrEP: results from a qualitative study. Transl Behav Med. 2020. https://doi.org/10.1093/tbm/ibz191 .
doi: 10.1093/tbm/ibz191
pubmed: 32065637
Morgan E, Dyar C, Newcomb M, D’Aquila R, Mustanski B. PrEP use and sexually transmitted infections are not associated longitudinally in a cohort study of young men who have sex with men in Chicago. AIDS Behav. 2019. https://doi.org/10.1007/s10461-019-02664-9 .
doi: 10.1007/s10461-019-02664-9
pubmed: 30680540
pmcid: 6511315
Streeck H, Janssen K, Crowell TA, Jessen H, Cordes C, Scholten S, et al. Prospective, multicenter study to assess point prevalence, incidence and recurrence of sexually transmitted infections in men who have sex with men in Germany: BRAHMS study [Internet] 2019. https://programme.ias2019.org/Abstract/Abstract/1906 . Accessed 30 Oct 2019.
Nguyen V-K, Greenwald ZR, Trottier H, Cadieux M, Goyette A, Beauchemin M, et al. Incidence of sexually transmitted infections before and after Pre-Exposure Prophylaxis for HIV: a cohort study. AIDS. 2017;32:523.
pmcid: 5865505
Koester K, Amico RK, Gilmore H, Liu A, McMahan V, Mayer K, et al. Risk, safety and sex among male PrEP users: time for a new understanding. Cult Health Sex. 2017;19(12):1301–13.
doi: 10.1080/13691058.2017.1310927
Auerbach JD, Hoppe TA. Beyond “getting drugs into bodies”: social science perspectives on pre-exposure prophylaxis for HIV. J Int AIDS Soc. 2015;18:19983. https://doi.org/10.7448/IAS.18.4.19983 .
doi: 10.7448/IAS.18.4.19983
pubmed: 26198346
pmcid: 4509897
Mabire X, Puppo C, Morel S, Mora M, Rojas Castro D, Chas J, et al. Pleasure and PrEP: pleasure-seeking plays a role in prevention and in sexual quality of life, and could Lead to PrEP initiation. Am J Men’s Health. 2019. https://doi.org/10.1177/1557988319827396 .
doi: 10.1177/1557988319827396
World Health Organization. Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people recommendations for a public health approach. Geneva: World Health Organization; 2011. p. 1–88.
Richens J, Imrie J, Copas A. Condoms and seat belts: the parallels and the lessons. The Lancet. 2000;355(9201):400–3.
doi: 10.1016/S0140-6736(99)09109-6
Roux P, Fressard L, Suzan-Monti M, Chas J, Sagaon-Teyssier L, Capitant C, et al. Is on-demand HIV pre-exposure prophylaxis a suitable tool for men who have sex with men who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial: JAIDS J Acquir Immune Defic Syndr. 2018. https://doi.org/10.1097/QAI.0000000000001781 .
doi: 10.1097/QAI.0000000000001781